Levels and patterns of expression of hypoxia-inducible factor-1α, vascular endothelial growth factor, glucose transporter-1 and CD105 in adenoid cystic carcinomas with high-grade transformation

Histopathology

Volumn 60, Issue 5, 2012, Pages 816-825

  Costa, Ana F ^a   Tasso, Marcelo G ^a   Mariano, Fernanda V ^a   Soares, Andresa B ^b   Chone, Carlos T ^a   Crespo, Agricio N ^a   Fresno, Manuel F ^c   Llorente, Jose L ^c   Suárez, Carlos ^c   de Araújo, Vera C ^b   Hermsen, Mario ^c   Altemani, Albina ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Adenoid cystic carcinoma; CD105; Glucose transporter 1; High grade transformation; Hypoxia inducible factor 1; Vascular endothelial growth factor

Indexed keywords

ENDOGLIN; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADENOID CYSTIC CARCINOMA; ANGIOGENESIS; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CONTROLLED STUDY; DENSITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT TRANSFORMATION; METASTASIS; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECURRENT CANCER; SALIVARY GLAND; TUMOR VOLUME;

ADULT; AGED; ANTIGENS, CD; CARCINOMA, ADENOID CYSTIC; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84859006688     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04128.x     Document Type: Article

References (40)

1. El-Naggar AK, Huvos AG. Adenoid cystic carcinoma. In Barnes L, Eveson JW, Reichart P, Sidransky D eds. World Health Organization classification of tumour. Pathology and genetics. Head and neck tumours. Lyon: IARC Press, 2005; 223-224.
2. Simpson RH, Pereira EM, Ribeiro AC, Abdulkadir A, Reis-Filho JS. Polymorphous low-grade adenocarcinoma of the salivary glands with transformation to high-grade carcinoma. Histopathology 2002; 41; 250-259.
3. Nagao T, Gaffey TA, Serizawa H et al. Dedifferentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases. Mod. Pathol. 2003; 16; 1265-1272.
4. Seethala RR, Hunt JL, Baloch ZW, Livolsi VA, Leon Barnes E. Adenoid cystic carcinoma with high-grade transformation: a report of 11 cases and a review of the literature. Am. J. Surg. Pathol. 2007; 31; 1683-1694.
5. Skalová A, Sima R, Vanecek T et al. Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am. J. Surg. Pathol. 2009; 33; 1137-1145.
6. Roy P, Bullock MJ, Perez-Ordoñez B, Dardick I, Weinreb I. Epithelial-myoepithelial carcinoma with high-grade transformation. Am. J. Surg. Pathol. 2010; 34; 1258-1265.
7. Costa AF, Altemani A, Vékony H et al. Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type. Cell. Oncol. 2011; 34; 369-379.
8. Costa AF, Altemani A, Hermsen M. Current concepts on dedifferentiation/high-grade transformation in salivary gland tumors. Patholog. Res. Int. 2011; 2011; 325965.
9. Cheuk W, Chan JK, Ngan RK. Dedifferentiation in adenoid cystic carcinoma of salivary gland. An uncommon complication associated with an accelerated clinical course. Am. J. Surg. Pathol. 1999; 23; 465-472.
10. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002; 2; 38-47.
11. Jögi A, Øra I, Nilsson H, Poellinger L, Axelson H, Pahlman S. Hypoxia-induced dedifferentiation in neuroblastoma cells. Cancer Lett. 2003; 197; 145-150.
12. Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S. Hypoxia-induced dedifferentiation of tumor cells: a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin. Cell Dev. Biol. 2005; 16; 554-563.
13. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 2000; 88; 1474-1480.
14. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004; 4; 891-899.
15. Behrooz A, Ismail-Beigi F. Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol. Sci. 1999; 14; 105-110.
16. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001; 276; 9519-9525.
17. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J. Bioenerg. Biomembr. 2007; 39; 251-257.
18. Haber RS, Rathan A, Weiser KR et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998; 83; 34-40.
19. Kalir T, Wang BY, Goldfischer M et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 2002; 94; 1078-1082.
20. Burstein DE, Nagi C, Kohtz DS, Lee L, Wang B. Immunodetection of GLUT1, p63 and phospho-histone H1 in invasive head and neck squamous carcinoma: correlation of immunohistochemical staining patterns with keratinization. Histopathology 2006; 48; 717-722.
21. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003; 9; 669-676.
22. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 2007; 8; 464-478.
23. Li C, Issa R, Kumar P et al. CD105 prevents apoptosis in hypoxic endothelial cells. J. Cell Sci. 2003; 116; 2677-2685.
24. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003; 17; 984-992.
25. Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc. Res. Tech. 2001; 52; 437-449.
26. Seeber LM, Horrée N, van der Groep P, van der Wall E, Verheijen RH, van Diest PJ. Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer 2010; 10; 307-317.
27. Bonfitto VL, Demasi AP, Costa AF, Bonfitto JF, Araujo VC, Altemani A. High-grade transformation of adenoid cystic carcinomas: a study of the expression of GLUT1 glucose transporter and of mitochondrial antigen. J. Clin. Pathol. 2010; 63; 615-619.
28. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998; 12; 149-162.
29. Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59; 5830-5835.
30. Bos R, Zhong H, Hanrahan CF et al. Levels of hypoxia-inducible factor-1alpha during breast carcinogenesis. J. Natl. Cancer Inst. 2001; 93; 309-314.
31. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol. Histopathol. 2007; 22; 559-572.
32. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002; 95; 1055-1063.
33. Vleugel MM, Greijer AE, Shvarts A et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J. Clin. Pathol. 2005; 58; 172-177.
34. Tomes L, Emberley E, Niu Y et al. Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res. Treat. 2003; 81; 61-69.
35. Moreno-Sánchez R, Rodríguez-Enríquez A, Marín-Hernández A, Saavedra E. Energy metabolism in tumour cells. FEBS J. 2007; 274; 1393-1418.
36. Mazurek S, Boschek CB, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J. Bioenerg. Biomembr. 1997; 29; 315-330.
37. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J. 2000; 14; 55-64.
38. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13; 9-22.
39. Kimura H, Weisz A, Ogura T et al. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J. Biol. Chem. 2001; 276; 2292-2298.
40. Sánchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabéu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 2002; 277; 43799-43808.